OFFICIAL

# FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

May 06, 2004

RECEIVED CENTRAL FAX CENTER

TO:

Examiner R. SCHNIZER

Group 1635

MAY 0 6 2004

**FROM** 

Lin Sun-Hoffman

Celera Genomics Corp.

(240) 453-3628

(FAX) (240) 453-3084

| FAX NO:                   | (703) 872-9306 |
|---------------------------|----------------|
| # OF PAGES (incl. cover): | 8              |

Re

U.S. Serial No. 09/820,788, filed March 30, 2001 Entitled "ISOLATED HUMAN DRUG METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG

METABOLIZING PROTEINS, AND USES THEREOF"

Atty. Docket No.: CL001207

### Examiner Schnizer;

Per our telephone conversation of today, please find enclosed a copy of the response to a restriction requirement that was filed in the United States Patent and Trademark Office on December 31, 2003 along with a copy of the date-stamped receipt evidencing the filing thereof.

Should you have any questions regarding this matter, please do not hesitate to contact me.

Please acknowledge receipt via facsimile or telephone.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

# TOF THE FOLLOWING IS ACKNOWLEDGED IN THE TED STATES PATENT AND TRADEMARK OFFICE:

Atty Docket No.: CL001207

ial No. 09/820.788 HUMAN DRUG-

Date: December 31, 2003

Due Date: January 2, 2004

Amendment (Restriction Response) 2-Month Extension of Time

MAIL STOP: PATENT APPLICATION Please date-stamp and return by mail

## RECEIPT OF THE FOLLOWING IS ACKNOWLEDGED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE:

Wei SHAO et al. In re Appln. Serial No. 09/820,788 Title: ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC AC:D MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF

Atty Docket No.: CL001207

Date: December 31, 2003 Due Date: January 2, 2004

Transmittal

XXX Request for 2-Month Extension of Time

Preliminary Amendment (Restriction Response)

IZING PROTEINS, AND S ENCODING HUMAN PROTEINS, NUCLEIC



MAIL STOP: PATENT APPLICATION

Please date-stamp and return by mail

PTO/SERG1 (03-03)

| Una   | dar the Par  | neowark Ri  | eduction Act of 1995                | na bersoni             | U.S. P  | atent end | Approved for use through 04/30/2003. OMB 0851-0031<br>nd Tradement Office; U.S. DEPARTMENT OF COMMERCE<br>of Information unless it displays a valid OMB control number. |  |  |
|---|--|-------------|-------------------------------------|------------------------|---|-----------|---|--|--|
|   | *  |             |                                     |                        | Application Number  |           | L001207   |  |  |
| TRANSMITTAL   |  | Filing Date | Ma                                  | March 30, 2001         |   |           |   |  |  |
| }   | FORM   |             | First Named Inventor                | We                     | Wei SHAO  |           |   |  |  |
| (to be  | (to be used for all correspondence after initial filing) |             | Art Unit                            | 16                     | 1635  |           |   |  |  |
|   |  |             | Examiner Name                       | R.                     | R. Schnizer   |           |   |  |  |
| <u> </u>  |  |             |                                     | Attorney Docket Number | r CL  | CL001207  |   |  |  |
| 10001   | Total Number of Pages in This Submission                 |             |                                     |                        |   |           |   |  |  |
|   |  |             |                                     | ENCL                   | OSURES (Check all   | that ap   |   |  |  |
|   | Fee Trans  |             |                                     |                        | Drawing(s)  |           | After Allowance Communication to a Technology Center (TC)  Appeal Communication to Board  |  |  |
| l '   | L Fe   | e Attach    | ed                                  |                        | icensing-related Papers                                     |           | of Appeals and Interferences Appeal Communication to TC   |  |  |
| ا النا  | Amendma  | nt/Reply    | ,                                   |                        | Petition<br>Petition to Convert to a                        |           | (Appeal Notice, Brief, Ruply Brief)   |  |  |
| <u> </u>  | Af   | ter Final   |                                     | LJ F                   | rovisional Application                                      | _         | Proprietary Information   |  |  |
| l l   | L AF   | fidavits/d  | lectaration(s)                      |                        | Power of Attorney, Revocation<br>Change of Correspondence A |           |   |  |  |
| 10  | Extension  | of Time     | Request                             |                        | erminal Disclaimer  |           | Other Enclosure(s) (please Identify below):   |  |  |
|   | Express Abandonment Request Request for Refund           |             |                                     |                        |   |           |   |  |  |
|   |  |             |                                     | <u></u>                | D, Number of CD(s)  |           |   |  |  |
|   |  |             |                                     | Remar                  |   |           |   |  |  |
|   | Certified (<br>Document                                  |             | nonty                               |                        | <del></del>   |           |   |  |  |
|   | Response<br>Incomplet                                    |             |                                     |                        |   |           |   |  |  |
| ' '   |  |             |                                     |                        |   |           |   |  |  |
| Į į   |  |             | to Missing Parts<br>FR 1.52 or 1.53 |                        |   |           |   |  |  |
| İ   |  |             |                                     |                        |   |           |   |  |  |
| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT  |  |             |                                     |                        |   |           |   |  |  |
| Firm  |  |             |                                     |                        |   |           |   |  |  |
| Or Ciri Sair-Hollings, Fil.D., Registation No. 47,900   |  |             |                                     |                        |   |           |   |  |  |
| Individual Signature  |  |             |                                     |                        |   |           |   |  |  |
| Date  | Date December 31, 2003                                   |             |                                     |                        |   |           |   |  |  |
|   |  |             |                                     |                        |   |           |   |  |  |
| CERTIFICATE OF TRANSMISSION/MAILING  I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: |  |             |                                     |                        |   |           |   |  |  |
| Typed o   | Typed or printed   |             |                                     |                        |   |           |   |  |  |
| Signatu   | ire  |             |                                     |                        |   |           | Date  |  |  |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Three will vary depending upon the individual case. Any comments on the amount of time you require to complete this form anti/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, cell 1-800-PTO-9199 (1-800-786-9199) and select option 2.

# HECEIVED CENTRAL FAX CENTER IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wei SHAO et al.

Serial No. 09/820,788

Art Unit: 1635

Examiner: R. Schnizer

240 453 3084 TO 97038729306

Filed: March 30, 2001 Atty. Docket: CL001207

For: ISOLATED HUMAN DRUG-METABOLIZING PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN DRUG-METABOLIZING PROTEINS, AND USES THEREOF

### PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

This is in response to a restriction requirement issued by Examiner Schnizer on October 2, 2003. Filed herewith is a request for a two-month extension of time.

By way of response, Applicants hereby elect claim group III, claims 4, 5, 8-11, 13, 22 and 23 directed to nucleic acid molecules, vectors, host cells, etc., for examination and have canceled claims corresponding to the non-elected groups I-II, IV and V-X.